Excluding Cancer Doctors From Initial Part B Pilots Would Avoid Political Blowback

June 06, 2018
The administration would be wise to test drug price-cutting policies on ophthalmologists and rheumatologists before expanding demonstrations to cover more politically powerful cancer doctors, health care analysts say, though ophthalmologists and rheumatologists stress that they helped kill the Obama administration's proposed Part B demo. Colin Edgerton, chair of the American College of Rheumatology's Committee on Rheumatologic Care, agreed that oncologists have a lot of clout. "Public education and awareness about cancer is arguably higher than for any other disease category...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.